Tirzepatide is a novel dual GIP/GLP-1 receptor agonist that has demonstrated breakthrough efficacy in the treatment of type 2 diabetes mellitus. As a strictly regulated prescription drug, its acquisition and use must comply with clear medical standards.
How to Purchase Tirzepatide
Overseas Purchase
Patients may consult and purchase tirzepatide at hospital pharmacies or legitimate drugstores in countries/regions where the medication is marketed.
Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients should make budgetary plans in advance.
Purchase through Medical Service Institutions
Patients may consult domestic overseas medical service institutions collaborating with international pharmacies or pharmaceutical companies.
These institutions typically provide legal import channels and offer professional consultation and guidance.
Precautions for Purchase and Use of Tirzepatide
Prescription and Dosage Management
Standard Initial Dose: For adults, the first dose is 2.5 mg administered subcutaneously once weekly.
Dosage Adjustment: After 4 weeks, the dose may be increased to a maintenance dose of 5 mg, and thereafter may be escalated by 2.5 mg at 4-week intervals.
Maximum Dose Limit: No more than 15 mg once weekly.
Administration Time: Administer on the same fixed day each week; avoid arbitrary changes.
Contraindicated Populations
Patients with a history of hypersensitivity to any component of this medication.
Patients with diabetic ketoacidosis, diabetic coma or pre-coma, or type 1 diabetes mellitus.
Patients in emergency states such as severe infections or surgery.
Pregnant women or women of childbearing potential.
Usage Restrictions in Special Populations
Hepatic or Renal Impairment: Use with caution and enhance monitoring.
Elderly Patients: Due to age-related decline in physiological function, dosage adjustment and close observation are necessary.
Patients with Gastrointestinal Diseases: Use with caution in patients with severe gastroparesis, etc.
Drug Interactions
Oral Hypoglycemic Agents: Concurrent use with sulfonylureas, rapid-acting insulin secretagogues, or insulin preparations requires precautions against the risk of hypoglycemia.
Oral Contraceptives: May reduce the efficacy of contraceptives.
Authentication of Tirzepatide Authenticity
Physical Characteristic Identification
Form: Combined product of a prefilled syringe with a fixed injection needle.
Appearance: Colorless to slightly yellowish to slightly brownish transparent liquid or liquid with a slight milky luster.
pH Value: 6.5–7.5.
Osmolality Ratio: Approximately 1.
Formulation Composition Verification
2.5 mg strength: Each syringe contains 2.5 mg tirzepatide.
5 mg strength: Each syringe contains 5 mg tirzepatide.
Excipients: Disodium hydrogen phosphate heptahydrate 0.7 mg, sodium chloride 4.1 mg, hydrochloric acid (as needed), sodium hydroxide (as needed).
Identification of Quality Abnormalities
Discontinue use immediately if discoloration, turbidity, or suspended particles are observed in the liquid.
Do not use frozen products.
